Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valeria Barcella

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Multiple Sclerosis and Related Disorders|December 6, 2024
Effect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis-A real-world evidence studyJette Lautrup Frederiksen, Luca Massacesi, Helle Hvilsted Nielsen, et al.
Journal of Neurology|September 28, 2018
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Pietro Annovazzi, Laura Boffa, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 14, 2019
Impact of natural menopause on multiple sclerosis: a multicentre studyDamiano Baroncini, Pietro Osvaldo Annovazzi, Nicola De Rossi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2018
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life studyFrancesco Saccà, Roberta Lanzillo, Alessio Signori, et al.
Journal of Neurology|February 22, 2021
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy studySebastiano Bucello, Pietro Annovazzi, Paolo Ragonese, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 18, 2020
Cladribine vs other drugs in MS: Merging randomized trial with real-life dataAlessio Signori, Francesco Saccà, Roberta Lanzillo, et al.
JAMA Network Open|November 3, 2025
Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MSShalom Haggiag, Luca Prosperini, Massimo Filippi, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Multiple Sclerosis and Related Disorders|December 6, 2024
Effect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis-A real-world evidence studyJette Lautrup Frederiksen, Luca Massacesi, Helle Hvilsted Nielsen, et al.
Journal of Neurology|September 28, 2018
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Pietro Annovazzi, Laura Boffa, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 14, 2019
Impact of natural menopause on multiple sclerosis: a multicentre studyDamiano Baroncini, Pietro Osvaldo Annovazzi, Nicola De Rossi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 26, 2018
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life studyFrancesco Saccà, Roberta Lanzillo, Alessio Signori, et al.
Journal of Neurology|February 22, 2021
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy studySebastiano Bucello, Pietro Annovazzi, Paolo Ragonese, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 18, 2020
Cladribine vs other drugs in MS: Merging randomized trial with real-life dataAlessio Signori, Francesco Saccà, Roberta Lanzillo, et al.
JAMA Network Open|November 3, 2025
Comparative Effectiveness of Cladribine and S1P Receptor Modulators in Treatment-Naive Relapsing-Remitting MSShalom Haggiag, Luca Prosperini, Massimo Filippi, et al.
Pageof 2